Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Merck’s Keytruda Approved By U.S. FDA To Treat Early Breast Cancer In Combo With Chemotherapy

By John F. Heerdink, Jr.

Reportedly, U.S FDA has granted approval to Merck & Co Inc.’s (MRK) immunotherapy Keytruda for the treatment of an early form of breast cancer, used in combination with chemotherapy.

The U.S. Food and Drug Administration’s approval is for the treatment of triple-negative breast cancer (TNBC), which is aggressive and difficult to treat with an increased risk of recurrence. Approximately10-15% of patients with breast cancer are diagnosed with TNBC, and is more common in people below 40 years of age and who are African American.

The trial data from over 1,000 patients displayed that the drug, in combination with chemotherapy before surgery and then used as monotherapy after surgery, helped protract the time that a patient remained cancer-free. Keytruda has been gaining approvals for treating 30 types of cancer, pushing the drug’s sales which have overtaken those of rival immunotherapies by Bristol Myers Squibb and Roche. Sales of Keytruda, now approved in the United States to treat, touched $14.4 billion in 2020.

Merck & Co., Inc. (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some of the world’s most challenging diseases for more than a century. They are committed to increasing health care access and continue to be at the leading edge of research. Merck has the industry’s largest immuno-oncology clinical research program. To learn more about Merck (MRK) and to track its ongoing progress please visit the Vista Partners Merck Coverage Page.

If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus. 

Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research. Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

(Read Original Story: U.S. FDA approves Merck's Keytruda combo for early breast cancer treatment in Reuters)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us